• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


H&T Presspart Low GWP Banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

TFF Pharmaceuticals raises over $8 million, announces executive appointments

DPI developer TFF Pharmaceuticals said that is has raised $8.17 million through a Series A preferred stock offering and that it will use the funds for R&D. In April 2018, the company announced that it had raised $14 million for development of inhaled drugs, also through a Series A preferred stock offering.

In the past year, TFF has received patents in the US and Europe for its DPI particle technology, which is licensed from the University of Texas at Austin. The company says that it has more than 30 patents and applications related to the thin film freezing technology.

TFF CEO Glenn Mattes commented, “We are grateful to our investors for their continued support of our groundbreaking efforts to create new treatments of pulmonary diseases and conditions, like lung transplant, severe asthma, COPD and pulmonary infections,”

The company also announced the appointments of Kirk Coleman as Chief Financial Officer and Randy Thurman as a board member and chairman of the audit committee. Coleman, who was most recently an executive officer of Steelhead Capital Management, said, “I am very excited to be working with TFF Pharmaceuticals. The company’s breakthrough technology, strong foundation, seasoned leadership and loyal investors have brought them rapid progress and early success. I look forward to contributing even more to that success.”

Thurman, who was Founder, Chairman and CEO of VIASYS Healthcare and President of Rorer Pharmaceuticals and Rhone-Polenc Rorer, commented, “I look forward to lending my industry experience to TFF Pharmaceuticals in order to continue their growth trajectory and make a positive impact on their progress.”

Read the TFF Pharmaceuticals press release.

Share

published on May 30, 2019

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Proveris_180x150a
    © 2025 OINDPnews